Earth Science Tech Inc. (OTCQB: ETST), a strategic holding company with operations in healthcare, pharmacy, technology, telemedicine, real estate, and consumer products, is betting on artificial intelligence and in-house technological expertise to fuel sustainable growth and long-term value. At the company’s recent Annual Meeting of Shareholders, Chief Technology Officer Chris Rose outlined how a focused IT infrastructure department has enabled ETST to reduce costs, streamline operations, and widen profit margins across its pharmacy and telemedicine platforms.
Central to this strategy is a build-versus-buy approach. “We build now instead of buy, supported by advancements in and our leverage of AI,” Rose said. “We’ve built our own ETST-wide software and data platform that ties together the three pharmacies, our curative telehealth business, and My Online Consultation doctor’s” services. This proprietary platform allows the company to integrate its various business lines, creating operational synergies that would be difficult to achieve with off-the-shelf solutions.
The implications extend beyond internal efficiencies. By developing its own technology stack, ETST has been able to offer its in-house tools to other clinics as a white-label service, potentially creating a new revenue stream. This move positions the company not just as a healthcare provider but also as a technology enabler for other medical practices, which could drive additional growth and diversify its income sources.
Technology is also playing a key role in ETST’s marketing efforts. The company uses digital tools to increase patient and customer retention and to foster brand loyalty. In a competitive healthcare landscape, retaining patients is often more cost-effective than acquiring new ones, and ETST’s tech-driven approach aims to strengthen these relationships.
For investors, the emphasis on technology and AI signals a forward-looking strategy that could yield tangible financial benefits. By cutting costs and improving margins, ETST aims to demonstrate that its investments in IT are paying off. The company’s ability to commercialize its platform as a white-label service further suggests that its technology has value beyond its own operations, potentially attracting interest from other healthcare providers.
The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution to millions of followers, and a full array of tailored corporate communications solutions.
As ETST continues to develop its technology stack, the market will be watching to see whether these initiatives translate into sustained financial performance. For a company operating in the highly competitive healthcare and telemedicine space, the ability to innovate internally while also monetizing those innovations externally could prove to be a significant differentiator. More details can be found at BioMedWire.
